welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Safety Study of BLS-M22 in Healthy Volunteers

key information

study id #: NCT03789734

condition: Muscular Dystrophy, Duchenne

status: recruiting


BLS-M22 is being developed as an anti-myotatin agent for the treatment of Duchenne Muscular Dystrophy (Muscular Dystrophy). A total of 37 subjects participated in this study to confirm the safety of BLS-M22.

intervention: BLS-M22, Placebo

mechanism of action: Anti-myostatin to promote muscle growth

results: https://clinicaltrials.gov/ct2/show/results/NCT03789734

last updated: November 14, 2020